Filing Flows › Exagen (XGN) › R&D spending
Exagen (XGN) R&D spending by quarter
Exagen's R&D spending was $1.4M in Q2 2026 (second quarter 2026), -8% from Q1 2026. Over the last 7 quarters it ranged from $1.3M (Q1 2025) to $1.8M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $1.4M | -8% | -4% |
| Q1 2026 | $1.6M | -12% | +21% |
| Q4 2025 | $1.8M | +2% | +6% |
| Q3 2025 | $1.7M | +17% | — |
| Q2 2025 | $1.5M | +15% | — |
| Q1 2025 | $1.3M | -22% | — |
| Q4 2024 | $1.7M | — | — |
Q2 2026 at a glance
Exagen, Q2 2026: revenue $19.9M (+16% year over year), operating margin -8.6%, net loss $3.2M, operating cash flow $4.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Exagen's R&D spending?
Exagen's R&D spending was $1.4M in Q2 2026 (second quarter 2026), -8% from Q1 2026.
How has Exagen's R&D spending changed?
Over the last 7 quarters it ranged from $1.3M (Q1 2025) to $1.8M (Q4 2025).